Introduction {#sec1_1}
============

Cerebrovascular disease (CVD) is a global problem of modern healthcare leading to high mortality rates. The percentage of mortality due to acute and chronic CVD is 11.13% \[[@B1]\], which makes it the second cause of death in the world \[[@B2]\]. High rates of disability, mortality and economic burden caused by CVD underline the necessity of broad research into various aspects of the etiology, clinical presentation and progression of vascular brain pathology.

Both acute and chronic CVD are predominantly accompanied by rheological abnormalities, the latter occurring in a number of cases due to an increase in blood corpuscles. One of the reasons of elevated erythrocyte and/or platelet count is Ph-negative myeloproliferative neoplasms, i.e. excessive proliferation of one or more cell lines of myelopoiesis \[[@B3]\].

High rate of hematocrit significantly increases the risk of thrombotic complications in arterial and venous vessels. Thrombosis of the carotid and vertebrobasilar region with hemispheric infarction is a life-threatening condition. Mortality rates in patients with Ph-negative myeloproliferative disorder (Ph-MPD) are 1.5 times higher than in the general population; hence, it is becoming increasingly important to elucidate the mechanisms of large- and small-vessel thrombotic events \[[@B4],[@B5]\]. The present study aims at identifying clinical and laboratory features of CVD in the setting of Ph-MPD.

Methods {#sec1_2}
=======

The study included 167 patients: 102 patients with Ph-MPD and the control group comprising 65 patients with CVD. According to MPD subtype, the patients were divided into three groups (WHO 2008): patients with essential thrombocythemia (ET) (37%, n = 38, male/female 7/31, age 52 ± 7 years), those with polycythemia vera (PV) (40%, n = 41, male/female 20/21, age 50 ± 6 years) and those with primary myelofibrosis (PM) (23%, n = 23, male/female 5/18, age 54 ± 4 years).

Patients with advanced stages of cardiac disease, renal and/or liver failure, hypertension or carotid atherosclerosis were excluded from the study group. The control group included patients with CVD and concomitant cardiovascular pathology. Age \>58 years was an exclusion criterion for all groups.

All patients underwent a thorough clinical and neurological exam: MRI scan of the brain, MR angiography, MR imaging of the cerebral venous sinuses; duplex sonography of the brachiocephalic arteries with the measurement of flow-dependent dilation of the brachial artery (as an endothelial dysfunction test with a normal cut-off of \>10%); complex blood tests (including hemorheology, hemostasis, complete blood count, platelet and erythrocyte aggregation, morphofunctional properties of red blood cells), and a specific biochemical tourniquet test (applied for endothelial dysfunction estimation).

Results {#sec1_3}
=======

In 79% (n = 81) of cases in the study group (with Ph-MPD), patients had chronic CVD, with the most frequently identified symptoms being asthenia (92%) and headache (72%). Other manifestations such as vestibular disorders were observed in 14% patients (n = 11), motor disorders in 5% (n = 4) and sensory disorders in 17% (n = 14) of cases. Headache in Ph-MPD patients was more frequently (86%) associated with PM, while in patients with PV and ET it was equally distributed (70%). The main clinical features of headache in patients with Ph-MPD were as follows: constant, of moderate intensity, often associated with photopsia. Neurological symptoms in 53% of cases with chronic CVD (n = 43) were associated with focal changes of the brain on MRI localized in the subcortical area of the frontal and parietal lobes. Of note, no lesions were observed in the deep subcortical white matter - this may as well be attributed to our specific exclusion of patients with hypertension, heart rhythm dysfunction and carotid atherosclerosis.

Twenty-one (21%) patients suffered an acute cerebrovascular accident, 8 of them had thrombotic occlusion of one of the internal carotid arteries (ICA) leading to hemispheric infarcts. We observed a male patient with ET aged 52 years who had a right-hemispheric infarction due to a thrombotic occlusion of the unilateral ICA (fig. [1a](#F1){ref-type="fig"}). After 48 h, the same patient had a recovery of blood flow in the right middle cerebral artery, as shown on the MR angiography (fig. [1b](#F1){ref-type="fig"}).

Thirteen patients had small cortical infarctions, possibly related to hemorheological micro-occlusion. Endothelial function (as measured by ultrasound) was severely impaired in all study groups, the lowest degree of vasodilator activity being specific for patients with a history of stroke (p = 0.011).

Hemorheologic and hemostasis abnormalities were not statistically significantly changed between subtypes of Ph-MPD, which allowed to view them as a whole group. The studied blood parameters compared to controls (MPD vs. chronic and acute CVD) are presented in table [1](#T1){ref-type="table"}.

Erythrocyte deformability characteristics in patients with CVD and MPD differ significantly not only from reference values, but from patients in the control group (CVD without MPD). There were no statistically significant differences between levels of von Willebrand factor and antithrombin III in patients of both study and control groups. Hematocrit levels were higher in patients with Ph-MPD, while fibrinolytic activity did not differ between groups (though it was lower than the reference values).

Endothelial dysfunction rates were lower in patients with Ph-MPD compared to CVD patients without this pathology. Athrombogenic potential is decreased predominantly due to the antiaggregational and fibrinolytical components, while the anticoagulational function of the endothelium remained relatively intact.

Discussion {#sec1_4}
==========

CVD may present as an initial manifestation of Ph-MPD \[[@B6]\]. Chronic brain ischemia often manifests itself with headache and/or asthenia \[[@B7]\]. There exists a firm link between hematological characteristics and cephalgia, supported by several studies \[[@B8],[@B9]\] where it has been demonstrated that in PV and ET, headache is often a first symptom of Ph-MPD \[[@B10]\]. Our findings confirm these data, with as much as 70% of patients referring to their physician with headache as the main complaint (which preceded the diagnosis of Ph-MPD). Headache presenting as a first and foremost neurological complaint was most frequently of a secondary origin and was closely connected to the degree of platelet count. Patients with Ph-MPD present with focal changes in the subcortical white matter in the frontal and parietal lobes. We suggest that this may be due to the vascular architecture of the terminal branches of the middle cerebral artery, which, descending from the convex, are more prone to thrombosis. Endothelial dysfunction increases the risk of thrombosis in the microcirculatory setting as well as in large vessels.

Conclusion {#sec1_5}
==========

\(1\) Headache (predominantly of a secondary origin) is a major clinical presentation of MPD, often being one of the earliest neurological symptoms. (2) MRI changes include cortical-subcortical lesions of vascular origin often not presenting clinically 'silent' brain lesions. (3) The lowest endothelial dysfunction rates were observed in patients with stroke, which confirms the decrease of the functional compensating capacity of the vascular endothelium leading to acute cerebrovascular events. (4) MPD, while remaining un- or underdiagnosed, presents a major concern in the cerebrovascular setting.

![**a** Patient R., 52 years. Massive right-hemispheric infarction due to thrombotic occlusion of the ICA (first 24 h). **b** Same patient. Blood flow recovery in the right middle cerebral artery (MR angiography, 48 h after stroke).](cee-0006-0066-g01){#F1}

###### 

Hemorheology and hemostasis parameters in CVD patients with or without Ph-MPD

                           Stroke (with MPD)                            Stroke (without MPD)                           Chronic CVD (with MPD)                         Chronic CVD (without MPD)   Reference values
  ------------------------ -------------------------------------------- ---------------------------------------------- ---------------------------------------------- --------------------------- ------------------
  ADP-PA                   28.2±3.01[\*](#T1F1){ref-type="table-fn"}    38.3±4.3                                       29.5±3.1                                       41.4±4.5                    40--46
                           p = 0.001                                                                                                                                                              
  Adr-PA                   29.5±3.2                                     35.4±4.6                                       25.01±2.8                                      36.8±4.2                    37--43
  RBC deformity            0.43±0.037[\*](#T1F1){ref-type="table-fn"}   0.51±0.043[\*\*](#T1F2){ref-type="table-fn"}   0.45±0.044[\*\*](#T1F2){ref-type="table-fn"}   0.53±0.023                  0.52--0.55
                           p = 0.0012                                   p = 0.013                                      p = 0.022                                                                  
  Aggregate stability, s   267.9±18.8[\*](#T1F1){ref-type="table-fn"}   185±20.6                                       210.5±16.7                                     125.6±14.5                  79--110
                           p = 0.0031                                                                                                                                                             
  von Willebrand factor    111±9.3                                      98.6±10.5                                      117.5±12.8                                     104.2±10.6                  79--110
  Hematocrit               50±2.27[\*](#T1F1){ref-type="table-fn"}      44.6±2.81                                      46.4±2.9                                       39±2.6                      35--45
                           p = 0.0062                                                                                                                                                             
  Antithrombin III         95.6±8.27                                    110.4±10.9                                     112.5±13.2                                     105.4±10.9                  71--115
  Fibrinolytic activity    12.7±0.11[\*](#T1F1){ref-type="table-fn"}    17.2±0.12                                      13.3±0.11[\*\*](#T1F2){ref-type="table-fn"}    18.6±0.14                   14--18
                           p = 0.018                                                                                   p = 0.016                                                                  
  Fibrinolysis index       0.60±0.05[\*](#T1F1){ref-type="table-fn"}    0.9±0.012                                      0.58±0.01[\*\*](#T1F2){ref-type="table-fn"}    1.0±0.05                    0.8--1.2
                           p = 0.022                                                                                   p = 0.036                                                                  

ADP-PA = Adenosine diphosphate-induced platelet aggregation; Adr-PA = adrenaline-induced platelet aggregation; RBC = red blood cell.

Statistically significant differences between groups, p \< 0.05 (stroke with MPD vs. reference).

Study versus control group.
